Clinical Development Containment Genetics Licensing 
The Pharma Data
NOVEMBER 4, 2020
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8
pharmaphorum
MAY 4, 2022
In testing new treatments, what is promising in animal models may not transfer particularly well to humans, which helps to explain why there is a 90% failure rate during clinical development. Once selected, Quris can in-license them, progress them through to phase 1 trials and, those that succeed, can be licensed to pharma companies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
APRIL 24, 2023
Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. For rare disease studies where there is little or no clinical trial experience, outcome assessments would have to be validated within a clinical development program.
The Pharma Data
JANUARY 21, 2021
Session: Expanding Targetable Genetic Alterations in NSCLC Mini Oral Session Date and Time: January 31, 2021, 14:20 SGT (January 30, 2021 10:20 p.m. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.
XTalks
AUGUST 15, 2023
Akeega is a dual-action tablet (DAT) that contains the company’s androgen receptor-targeting hormone therapy Zytiga (abiraterone acetate) and PARP inhibitor (poly [ADP-ribose] polymerase inhibitor) niraparib. Niraparib is also sold by GSK under the name Zejula in other indications. In April 2016, Janssen Biotech, Inc.
The Pharma Data
NOVEMBER 3, 2020
Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, announced today the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical candidate, LB-001 for the treatment methylmalonic acidemia (MMA). LEXINGTON, Mass.,
The Pharma Data
OCTOBER 26, 2020
Fast Track designation allows for early and frequent communication with the FDA throughout the entire drug development and review process. It may also allow for priority or rolling review of a company’s Biologics License Application (BLA). There are no therapies approved by the FDA for the treatment of neuronopathic Gaucher disease.
Expert insights. Personalized for you.
40 
Let's personalize your content